Overview

TT-00973-MS Tablets in Patients With Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, open-label, phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TT-00973-MS tablets in patients with solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
TransThera Sciences (Nanjing), Inc.